Meme Karsinom Patolojisi

Li CI, Anderson BO, Daling JR, et al. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11): 1421-1424. doi:10.1001/jama.289.11.1421

Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9): 1046-1052. doi:10.1038/sj.bjc.6602787

Dillon DA, Guidi AJ, Schnitt SJ. Pathology of invasive breast cancer. In: Diseases of the Breast, 4th ed, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott, Williams and Wilkins, Philadelphia 2009.

Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41): 134-138. doi:10.1093/jncimonographs/lgq035

Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86(3): 429-438. doi:10.1002/(sici)1097-0142(19990801)86:3<429::aid-cncr11>3.0.co;2-y

Grabowski J, Salzstein SL, Sadler GR, et al. Intracystic papillary carcinoma: a review of 917 cases. Cancer. 2008;113(5): 916-920. doi:10.1002/cncr.23723

Pinder SE, Duggan C, Ellis IO, et al. UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103(1): 94-100. doi:10.1038/sj.bjc.6605718

Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat. 1986;7(3): 171-180. doi:10.1007/BF01806247

Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features. Cancer. 1991;68(12): 2602-2607. doi:10.1002/1097-0142(19911215)68:12<2602::aid-cncr2820681214>3.0.co;2-i

Wärnberg F, Nordgren H, Bergh J, et al. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. Eur J Cancer. 1999;35(5): 714-720. doi:10.1016/s0959-8049(99)00010-6

Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer. 1997;80(9): 1798-1802. doi:10.1002/(sici)1097-0142(19971101)80:9<1798::aid-cncr15>3.0.co;2-0

Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast. Long-term followup. Cancer. 1974;34(3): 554-563. doi:10.1002/1097-0142(197409)34:3<554::aid-cncr2820340313>3.0.co;2-7

Page DL, Kidd TE Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12): 1232-1239. doi:10.1016/0046-8177(91)90105-x

Morrow M, Schnitt SJ. Lobular carcinoma in situ. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds), Lippincott-Raven, Philadelphia 1995.

Middleton LP, Palacios DM, Bryant BR, et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol. 2000;24(12): 1650-1656. doi:10.1097/00000478-200012000-00009

Sasson AR, Fowble B, Hanlon AL, et al. Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer. 2001;91(10): 1862-1869. doi:10.1002/1097-0142(20010515)91:10<1862::aid-cncr1207>3.0.co;2-#

Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw. 2006;4(5): 511-522. doi:10.6004/jnccn.2006.0041

King TA, Pilewskie M, Muhsen S, et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol. 2015;33(33): 3945-3952. doi:10.1200/JCO.2015.61.4743

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002;41: 154.

Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer. 2008;113(7): 1511-1520. doi:10.1002/cncr.23811

Winchester DJ, Chang HR, Graves TA, et al. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg. 1998;186(4): 416-422. doi:10.1016/s1072-7515(98)00051-9

Santiago RJ, Harris EE, Qin L, et al. Similar long term results of breast conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer. 2005;103(12): 2447-2454. doi:10.1002/cncr.21071

Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003;163(18): 2149-2153. doi:10.1001/archinte.163.18.2149

Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1): 41-48. doi:10.1200/JCO.2005.03.111. Erratum in: J Clin Oncol. 2013;31(23): 2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]

Ferlicot S, Vincent-Salomon A, Médioni J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer. 2004;40(3): 336-341. doi:10.1016/j.ejca.2003.08.007

Liu GF, Yang Q, Haffty BG, et al. Clinical pathologic features and long term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2009;75(5): 1304-1308. doi:10.1016/j.ijrobp.2008.12.070

Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J adiat Oncol Biol Phys. 2004;59(1): 152-159. doi:10.1016/j.ijrobp.2003.10.029

Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 2008;111(3): 541-547. doi:10.1007/s10549-007-9809-z

Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology. 2002;34(4): 309-314. doi:10.1080/00313020220147113

Huober J, Gelber S, Goldhirsch A, et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012;23(11): 2843-2851. doi:10.1093/annonc/mds105

Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol. 2001;32(6): 583-589. doi:10.1053/hupa.2001.24988

Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1): 166-173. doi:10.1245/s10434-006-9124-7

Dave G, Cosmatos H, Do T, et al. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys. 2006;64(3): 771-775. doi:10.1016/j.ijrobp.2005.08.024

Vranic S, Bender R, Palazzo J, et al. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol. 2013;44(3): 301-309. doi:10.1016/j.humpath.2012.01.002

McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966;195(5): 388-390.

Horowitz DP, Sharma CS, Connolly E, et al. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3): 350-353. doi:10.1016/j.breast.2012.02.013

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8): 731-739. doi:10.1056/NEJMoa1714448

Vranic S, Tawfik O, Palazzo J, et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol. 2010;23(5): 644-653. doi:10.1038/modpathol.2010.50

D'Arcy C, Quinn CM. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol. 2019;72(1): 7-11. doi:10.1136/jclinpath-2018-205485

Robbins GF, Shah J, Rosen P, et al. Inflammatory carcinoma of the breast. Surg Clin North Am. 1974;54(4): 801-810. doi:10.1016/s0039-6109(16)40383-x

McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002;8(12): 3857-3862